Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Immuneering CorporationNASDAQ: IMRX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $180.48K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $793.21K. Over 3 fiscal years it compounded at +64.1% a year.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $180.48K or moves back toward the trailing-twelve-month quarterly average of $198.3K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 698.89K USD
- Year-over-year change
- —
- 4-year CAGR
- -11.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 698.89K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 158.12K | -86.3% |
| FY2021 | 2021-12-31 | 1.15M | — |
Cost of Revenue vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 cost of revenue of $793.21K is the 8th highest of the 11 companies compared; the peer median is $5.16M.
- Its year-over-year change of +354.2% is the highest of 6, against a peer median of -43.5%.
- Over three fiscal years its annual growth of +64.1% compares with a peer median of +11.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $40.05M | — | — | 698.0% | |
| LTM Mar 2026 | $21.94M | — | — | 77.7% | |
| LTM Mar 2026 | $17.11M | +85.4% | +27.3% | 848.5% | |
| LTM Mar 2026 | $16.18M | -62.1% | -87.7% | 22.8% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $4M | — | — | 8.8% | |
| LTM Mar 2026 | $1.21M | — | — | 1.7% | |
| LTM Mar 2026 | $793.21K | +354.2% | +64.1% | — | |
| LTM Mar 2026 | $27K | — | — | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $16K | +220.0% | — | — |
| LTM Mar 2026 | -$101K | -104.8% | -1.1% | 44.9% | |
| Peer median (excluding IMRX) | $5.16M | -43.5% | +11.3% | 33.8% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.08M | 316.95K | 0 | 0 | 0 |
| Cost of Revenue | 1.15M | 158.12K | 0 | 0 | 698.89K |
| Gross Profit | 926.89K | 158.83K | 0 | 0 | (698.89K) |
| Gross Margin | 44.6% | 50.1% | — | — | — |
| Research & Development | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
| Selling, General & Admin | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M |
| Operating Expenses | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M |
| Depreciation & Amortization | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K |
| EBITDA | (33.68M) | (51.47M) | (58.06M) | (63.69M) | (55.33M) |
| EBITDA Margin | -1619.5% | -16238.4% | — | — | — |
| Operating Income | (33.89M) | (51.74M) | (58.41M) | (64.07M) | (59.38M) |
| Operating Margin | -1629.2% | -16325.8% | — | — | — |
| Interest Income | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M |
| Income Before Tax | (33.84M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Pre-Tax Margin | -1627.1% | -15937.4% | — | — | — |
| Income Tax Expense | (307.49K) | 0 | 0 | 0 | 0 |
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Net Margin | -1612.3% | -15937.3% | — | — | — |
| EPS (Basic) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| EPS (Diluted) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| Weighted Avg Shares | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
| Weighted Avg Shares (Diluted) | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.